Grants for Small businesses - Science and Technology

Key aspects of the TSA: Multidisciplinary Collaboration: The success of the project should depend on the unique skills and perspectives of each partner. The application must clearly define the synergistic components that will facilitate and accelerate progress in melanoma in a way that could not be accomplished through independent efforts. The plans for interactions among all PIs and institutions involved must be clearly articulated. Collectively, the members of the research team should represent the appropriate diversity of expertise necessary for addressing the proposed research question. Participating institutions must be willing to resolve potential intellectual and material property issues and remove institutional barriers to achieving high levels of cooperation. The following components of the proposed multidisciplinary collaboration are encouraged but not required: It is strongly encouraged that the research team has a least one investigator, key personnel, or consultant who can provide input on the ultimate utility/applicability (short- or long-term) of the anticipated outcome(s) to the melanoma field and/or patient care. The inclusion of an early-career investigator is encouraged. An early-career investigator is defined as an independent, early-career researcher or physician-scientist within 7 years of receiving their first faculty appointment by the time of the full application deadline. Investigators in mentored positions, (e.g., postdoctoral fellows) are not eligible to be named as a PI on a TSA application. The inclusion of a military and/or U.S. Department of Veterans Affairs (VA) investigator is encouraged. A military or VA investigator is defined as an investigator who is active-duty, active reserve, active duty detailed to agencies outside of the Department of Defense (DOD), civilian DOD investigators, or an investigator at a VA research facility. If included as PI on the research team, the military/VA investigator should have a substantial role in the research and should not be included only for access to active-duty military and/or VA populations. Impact: The application must articulate the impact the proposed work, including basic research, will have on melanoma research and/or patient care. Outcomes from this award are expected to expedite the advancement of promising ideas toward clinical applications and/or improve the current state of the science/technology in the melanoma field. The proposed research must relate to at least one of the FY24 MRP Focus Areas in Section II.A.1. Preliminary Data Required: Applications must include preliminary data to support feasibility of the study. However, these data do not necessarily need to be derived from melanoma studies. Any unpublished, preliminary data presented should originate from the laboratory of at least one of the PIs or other member(s) of the research team.

The FY24 MRP Idea Award supports innovative, untested, exploratory, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods that address at least one of the FY24 MRP Focus Areas in Section II.A.1. Key aspects of the Idea Award: The intent of the Idea Award is to generate novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the proposed research. Research supported by the Idea Award must introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. The proposed project must be exploratory, hypothesis-driven, or hypothesis-generating research and be based on a well-developed study design and plan of analysis. Principal Investigators (PIs) new to the melanoma field are encouraged to apply. The Idea Award is NOT intended to expand or extend previously published findings or continue a line of research already established and /or funded in the PIs laboratory. Incremental advances, the next logical step, or merely switching the object or method of inquiry from one cancer to melanoma is not considered innovative. The expected outcome of research supported by this award is the generation of robust preliminary data to be used as a foundation for future melanoma-focused research projects. Inclusion of preliminary data is discouraged. PIs proposing projects already supported by significant preliminary data and/or other funding sources should consider applying to other FY24 MRP funding opportunities for which the inclusion of preliminary data is more appropriate or required. Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative nature of this award. If preliminary data are included, they should be unanticipated outcomes or results from an unrelated project or study.

The Black Equity & Excellence Fund supports community-based projects for the Black community of Central New York that promote and encourage self-sufficiency and improve the physical and economic conditions that affect quality of life. Donor Name: Central New York Community Foundation State: New York County: Madison County (NY), Onondaga County (NY) Type of Grant: Grant Deadline: 07/12/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: The Foundation encourages dialogue that will strengthen race-related matters and support social and educational growth in the community. Types of Projects Projects must benefit the Black community or build upon the capabilities of your organization. Projects that focus on one of the following interest areas would qualify for a Black Equity & Excellence grant: Black Creatives Black Leadership + Advancement Black LGBTQIA+ Black Mental Wellness Black Legacy + Generational Wealth Black Business Black Maternal Health Black Civic Engagement Black Youth + Students Black Tech Funding Information Project funding levels are as follows: Grassroots Organizations/Businesses with a Fiscal Sponsor: $10k and under Pilot programs or small projects: $11k-$25k Expansion of existing projects: $26k-$55k Large capital projects or renovations: $56k-$75k Eligibility Criteria To be eligible, prospective applicants must meet all of these requirements: Have Black leadership in the senior executive position. Have at least 51% Black membership on their Board or steering committee. Seek to explicitly serve the Black community by targeting any of the focus areas listed below 501(c)(3) tax-exempt nonprofit organizations, publicly supported organizations such as schools and municipalities, or organizations using a 501(c)(3) fiscal sponsor. The use of a fiscal sponsor from a non-Black organization is permitted. Organizations serving residents of Onondaga or Madison counties. Projects Not Supported The Foundation does not make grants for the following: Annual operating budgets, except when it is “seed” or “bridge” funding Endowments Religious purposes Loans or assistance to individuals Medical or academic research (except where requested by a donor) Activities that occurred before the Community Foundation’s decision date For more information, visit CNYCF.

The LGBTQIA+ National Grant provides eligible small businesses the chance to receive one of 25 grant packages totaling $25,000. Donor Name: Founders First Community Development Corporation State: All States County: All Counties Type of Grant: Grant Deadline:  05/28/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: Founders First is committed to increasing the number of diverse founder-led businesses generating over $1 million dollars in revenues. Benefits $25,000 in Small Business Grants The $25,000 fund will make investments to 25 LGBTQIA+ led businesses in the United States. Access To Resources Join the Founders First family and connect with like-minded entrepreneurs and gain exclusive access to webinars and other valuable resources. Eligibility Requirements Identify as a LGBTQIA+ business owner Must be a CEO, President, or Business Owner Have an active U.S. based business Business Annual Revenue does not exceed $5M Must have between 2 to 100 employees Minimum of 1 year in business For more information, visit Founders First CDC.

This program provides financial assistance to small business and commercial property owners in Jackson, Mississippi, to improve the appearance of their buildings and attract more customers and investors.

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinsons research. This award mechanism supports the full spectrum of research from basic science through clinical research.

The FY24 PCRP Implementation Science Award supports studies that are expected to bridge the gap between research, practice, and policy through establishment of a knowledge base of interventions, clinical practices/guidelines, tools, and policies that can be deployed to targeted populations at the appropriate time and point of need. For the purposes of this funding opportunity, an implementation science study accesses strategies used and develops tools to enhance the systematic uptake of evidence-based health interventions into clinical and/or community settings in order to improve patient outreach, patient outcomes, and/or the effectiveness of health care.Impact: Research supported by the Implementation Science Award is expected to have the potential for major, near-term impact that will accelerate the widespread adoption of evidence-based practices in prostate cancer care, prevention, and survivorship. Applications are expected to identify the prostate cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Applications must also include a detailed research transition plan that articulates the pathway to moving the projects findings to the next phase for widespread clinical impact after successful completion of the award. Research transition plans are encouraged to consider future strategies targeting the patient, physician/provider, community, and/or healthcare system levels as applicable.Community Engagement: Applications are required to include members of the targeted population and/or community in the development and execution of the research project where appropriate. The research team must include one or more prostate cancer consumer advocate(s) or member(s) of the community, who will be integral throughout the planning and performance of the research project. Consumer advocates and/or community-based members should be involved in the development of the research question, project design, oversight, recruitment, and evaluation and dissemination of outcomes, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings; communication between the research team and the community should be frequent and bidirectional. The consumer advocates can be individuals who have been diagnosed with prostate cancer, a direct caregiver for someone who has been diagnosed with prostate cancer, or other representatives from the targeted community who are positioned to effect change. The consumer advocates and/or community-based members should have a high level of knowledge of current prostate cancer issues and the appropriate background in prostate cancer research and/or clinical care to contribute to the project or be otherwise positioned within the target community to effect changes in behavior based on projected outcomes. A list of implementation science resources and community or advocacy organizations is provided at the end of the Implementation Science Award Information section.Health Equity and Disproportionately Affected Populations: Regardless of the FY24 PCRP Overarching Challenge(s) being addressed, all research projects are strongly encouraged to consider health equity (e.g., access to evidence-based care) and/or have a focus on addressing the needs of disproportionately affected populations in the application.Research Scope: The Implementation Science Award mechanism is intended to fund studies including, but not limited to, the following: Small-scale clinical trials (up to phase 2) that contain clear reporting and implementation strategies to narrow the research-to-practice timeline and improve care for prostate cancer survivors, particularly within disproportionately affected populations Interventions that focus on behavioral or lifestyle changes at the patient, provider, community, and/or policy level Comparative effectiveness research establishing the benefits and harms of emerging or standard-of-care interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings Development and evaluation of strategies to overcome barriers to health care access across the cancer care continuum Altering the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines.Preliminary data to support the scientific rationale and feasibility of the research approaches are required. These preliminary data do not need to have been generated solely in prostate cancer. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.Investigators proposing a clinical trial are highly encouraged to consider leveraging the PCRP Prostate Cancer Clinical Trials Consortium (https://pcctc.org) to facilitate the rapid initiation and completion of the trial.Correlative studies that are associated with ongoing clinical trials, and preclinical studies involving the use of animals do not meet the intent of the FY24 PCRP Implementation Science Award.Partnering Principal Investigator (PI) Option: The FY24 PCRP Implementation Science Award encourages applications that include meaningful and productive collaborations between two investigators. The PIs may have expertise in similar or disparate scientific and/or clinical disciplines, but each PI is expected to bring distinct contributions to the application. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.A Clinical Trial Option allows for studies proposing small-scale clinical trials with a focus on implementation science. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Applications proposing a clinical trial are expected to provide detailed plans for initiating the clinical study within the first year, including U.S. Food and Drug Administration (FDA) Investigational New Drug/Investigational Device Exemption application submission plans, within 60 days of the award.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Implementation Sciences Resources: Potential applicants for this award are encouraged to seek collaborations and access to appropriate study populations through the following (or similar) resources: CDMRP: Search the CDMRP awards database at https://cdmrp.health.mil. The North Carolina Louisiana Prostate Cancer Project (PCaP): The PCaP was supported by the PCRP to conduct prostate cancer health disparity studies and developed a large biorepository of health disparity-related epidemiological data and biospecimens that may be requested for use by the research community. Information on PCaP investigators, data, and specimens is available at https://pcap.bioinf.unc.edu. National Cancer Institute Center to Reduce Cancer Health Disparities: Search for health disparity research and researchers at https://crchd.cancer.gov/index.html. National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Community-Based Participatory Research (CBPR) Initiative: Contact the NIMHD at https://www.nimhd.nih.gov/programs/extramural/community-based-participatory.html for information on current CBPR programs and scientists and communities engaged in health disparity research. Cancer Prevention and Control Research Network (CPCRN): Contact the CPCRN at https://cpcrn.org/ for information on community participatory research to reduce cancer in disproportionately affected populations. Health Resources and Services Administration, Office of Minority Health: Search for health disparity programs and funded investigators at https://www.hrsa.gov/index.html. NIH Research Portfolio Online Reporting Tool (NIH RePORTER): Search for NIH awards at https://projectreporter.nih.gov/reporter.cfm. Defense Technical Information Center (DTIC): Search for Department of Defense (DOD) and other government-funded investigators through DTIC Technical Reports at https://discover.dtic.mil/. National Library of Medicine, NIH, PubMed: Search for investigators publishing studies on prostate cancer health disparities at https://www.ncbi.nlm.nih.gov/pubmed. U.S. Department of Education: Search for institutions that may have increased access to disproportionately affected populations at https://www2.ed.gov/about/offices/list/ocr/edlite-minorityinst.html. International Cancer Research Partnership: Search for investigators and studies relevant to health disparity that are supported by cancer research funders from several countries including the United States, European Union, United Kingdom, and Canada at https://www.icrpartnership.org. National Coalition for LGBT Health: For more information on programs focused on Lesbian, Gay, Bisexual, and Transgender (LGBT) research, policy, education, and training, search https://www.healthlgbt.org. National LGBT Cancer Network: To obtain more information, search https://www.cancer-network.org.In addition, the following is a list of potential community and/or advocacy organizations that applicants may find helpful to satisfy the requirement for community engagement within their proposed studies: the American Indian Health Care Association, National African American Outreach Program of the Patient Advocate Foundation, National Alliance for Hispanic Health, National Medical Association, National Rural Health Association, and Prostate Health Education Network, as well as international organizations such as the African-Caribbean Cancer Consortium, African Organization for Research and Training in Cancer, Europa Uomo, European Cancer Patient Coalition, Global Prostate Cancer Alliance, Malecare, Men of African Descent and Carcinoma of the Prostate Consortium, Prostate Cancer Transatlantic Consortium, Urban League, and The Prostate Net.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Implementation Science Award should not exceed $2.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $9.6M to fund approximately three PCRP Implementation Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The FY24 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY24 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research.The New Investigator Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.The New Investigator Transitioning category is designed to allow investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator Early Stage category or New Investigator Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PIs expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. Preliminary data may include unpublished results from the laboratory of the PI, research team or collaborators named on the application.Key elements of this award are as follows:Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.It is the responsibility of the PI to clearly and explicitly articulate the projects innovation and its potential impact on DMD. The projects impact to both DMD research and to individuals with DMD should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the IDA.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

The PRP EIRA supports research opportunities for investigators in the early stages of their careers. The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.

The Community Livability Grant (CLG) provides grants to community-based organizations for projects that promote healthy, complete, and resilient neighborhoods and respond to and respect the diversity of its residents. Donor Name: Prosper Portland State: Oregon County: All Counties Type of Grant: Grant Deadline: 05/31/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: 1 Year Details: Prosper Portland seeks proposals from community-based organizations for projects that foster vibrant and healthy neighborhoods and improve the prosperity of area residents and businesses. Priorities The CLG program prioritizes projects that benefit historically underserved communities and promote widely shared prosperity. For example, such projects would: Improve access to jobs and workforce development services. Support wealth creation opportunities for small business owners. Honor and enhance the neighborhood’s cultural diversity and history. Deliver a community asset tailored to the community’s expressed priorities and opportunities. Funding Information The total maximum grant award is $300,000; awards typically range from $10,000 to $50,000. The project must be completed within one year of the grant award. Uses of funds Funding for the Grant Program is through tax increment financing (TIF) and, therefore, is tied to permanent, physical improvements (including tenant improvements) of real property. (Temporary installations, ongoing administration, routine maintenance costs (such as regular inspections and routine repairs), equipment, working capital, or work that was completed previous to the grant agreement execution are not eligible.) Who is the CLG for? Nonprofit organizations, neighborhood and business associations, and neighborhood groups located within the Central Eastside, Gateway Regional Center, Interstate Corridor, Lents Town Center and North Macadam Tax Increment Finance (TIF) Districts are eligible. Eligibility Criteria Nonprofit organizations, neighborhood and business associations, and neighborhood groups. Groups formed solely for performing a project in a neighborhood should have a 501(c)3 or 501(c)6 nonprofit organization to serve as their fiscal agent. Private property owner or for-profit entity may be eligible if the applicant does the following: leases or provides space for no fee or at a substantially reduced rate to meet the needs of a nonprofit organization or community group (it is strongly encouraged to apply in partnership with the non-profit organization); and provides or proposes to provide a significant community benefit that adds to the livability for area residents. If awarded, applicant must produce documentation that grant funds will be used only for improvements to space occupied by a nonprofit or directly related to providing a community benefit, and benefits will be ongoing for a minimum of three years. Schools if: The project provides a broad community benefit, is accessible to the public, and has been approved by the school district or other owner with a three-year maintenance and public access plan. The proposed project does not support a core educational function (e.g., building or improving pre-K-12 classrooms). For more information, visit Prosper Portland.

The Greenhouse Accelerator Program Juntos Crecemos Edition is a five-month, mentor-guided program to support the acceleration of emerging Hispanic food and beverages innovations that are transforming the way consumers live their lives. Donor Name: PepsiCo State: All States County: All Counties Type of Grant: Program Deadline: 05/06/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: This edition is an extension of the initial Greenhouse Accelerator program launched in 2018, in collaboration with PepsiCo Juntos Crecemos, part of PepsiCo’s Pep+ transformation agenda, designed to provide short and long-term support to Hispanic small businesses. The mission is to identify up to 8 high-potential emerging Hispanic-owned food and beverage consumer packaged goods small businesses. Driving growth for Hispanic founders in the food and beverage industry with operating businesses in the U.S. Program Benefits What the Greenhouse Accelerator can offer you: Grants Guaranteed $20,000 USD grant for each finalist. Winner awarded an additional $100,000 USD Guidance Expert guidance and learning modules across all aspects of business development Network Access and exposure to PepsiCo network and resources, industry experts, VCs and investors Collaboration Unlocking of potential collaboration opportunities with PepsiCo Mentorship Hands-on mentorship and support for refining business models, fortifying strategies, and enhancing impact Growth Accelerated pathways to launch, scale, and grow your breakthrough innovations. Eligibility Requirements  Net-revenue between $100,000 to $2,000,000 USD in the last financial year Be a Hispanic-owned business licensed and operating in the United States Be willing to work with PepsiCo Greenhouse Accelerator mentors and public relations team throughout six-month Accelerator program and attend Accelerator events. An external third party will review all submissions. The selection committee will choose finalists based on the following criteria: A clear go-to-market strategy and plan for sustained in-market execution Post-prototype, ready for review with a multinational corporation or company Uniqueness in the market Balanced gender and ethnic diversity Clear & active social responsibility mission aligned with PepsiCo’s Juntos Crecemos Strategy Aligned with PepsiCo’s PepsiCo Positive Strategy Scalable business model. For more information, visit PepsiCo.

The Entertainment Business Interruption Fund is here to assist small businesses in the entertainment industry who were impacted by COVID-19 pandemic and the double Hollywood Strikes. Donor Name: LA Small Business Development Center Network State: California County: Los Angeles County (CA) Type of Grant: Grant Deadline: 05/24/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: The Entertainment Business Interruption Fund (BIF), funded by the American Rescue Plan (ARP), is designed to support qualified small businesses that serve the Entertainment Industry in Los Angeles County (County). Grant Awards Grant amounts are based on business revenue as shown on the most recently filed federal business tax return. Revenue Size: $1,000,000 – 3,000,000 Eligible Grant Size: $25,000 Revenue Size: equal or less than $999,999 Eligible Grant Size: $10,000. Eligible Uses of Funds The purchase of new certified equipment. Restock of liquidated inventory. Lease, rent, or mortgage payments. Payment of business debt accrued due to the COVID-19 pandemic and the 2023 double Hollywood Strikes. Costs resulting from the COVID-19 pandemic and related health and safety restrictions, or business interruptions or closures incurred because of the COVID-19 pandemic and the 2023 double Hollywood Strikes. Employee payroll expenses. Working capital to continue operations. Payment of outstanding business expenses (supplier management, etc.) Grant awards may not be used by awardee for regranting or for any uses or expenses that the awardee has been, or will be, reimbursed for under any federal program. Eligibility Requirements For the purpose of this Program, a “qualified small business” means a business that meets all of the following criteria, as confirmed by the office or fiscal agent through review of revenue declines, other relief funds received, credit history, tax returns, payroll records, and bank account validation: Must be a for-profit business with $3 million or less in annual gross revenue as reflected in Applicant’s most recently filed, federal business tax return. Must have experienced at least a 70% loss of revenue due to the COVID -19 Pandemic from March 1, 2020 to present, as well as the 2023 double Hollywood Strikes between May 1, 2023 – November 30, 2023. At least 70% of revenue must come from the Entertainment Industry sector. Loss must be equal to or greater than grant amount requested. Business must have been registered to do business legally in the state of California and/or any other applicable jurisdiction prior to December 30, 2021, or other similar business filings. Active business currently in operation that is in good standing with all local, state, and federal taxing and licensing authorities. Must have a current physical location within the County of Los Angeles as of May 2023. Negative economic impacts from COVID – 19 Pandemic March 1, 2020 – present, as well as the 2023 double Hollywood Strikes between May 1, 2023 – November 30, 2023. Must not have received a grant funded by the American Rescue Plan Act (ARPA) from Los Angeles County. Application must be submitted by a majority owner that is at least 18 years of age as of the date of application. For more information, visit LA Small Business Development Center Network.

The HealthTech Accelerator is a 90-day tech business accelerator exclusively for pre-Series A HealthTech startups focused on Digital Health, Healthcare Services, Health Sustainability and Wellness, Medical Devices and Equipment, Software, Femtech, Augumented Reality, Virtual Reality, PharmacyTech, Wearables and Quantified Self, etc. Donor Name: Tampa Bay Wave State: Florida City: Tampa Type of Grant: Program Deadline: 05/24/2024 Size of the Grant: Not Available Grant Duration: Less than 1 Year Details: HealthTech|X is the latest startup focused business accelerator launched by Tampa Bay Wave, a nationally-recognized nonprofit, in partnership with the University of South Florida Research & Innovation, The Florida High Tech Corridor, U.S. Economic Development Corporation and more. Other Wave partnerships include Accenture, hospitals and health systems, healthcare specific VC funds, JP Morgan Chase, Bank of America, Raymond James, and more. Selected companies are not required to relocate for the duration of the program but must plan for on-site participation in Tampa, FL during each of the three blocks of programming.  Criteria for Consideration Business built with proprietary technology creating the next-generation of health technology products & solutions Dedicated management of at least two full-time people Ability to travel to Tampa at least 3 times during the 90-day program Proof of market validation Investable and/or scalable business Viable business plan Financial runaway of at least 6-12 months. For more information, visit Tampa Bay Wave.

The City of Alpena Downtown Development Authority (the “DDA”) established its Façade Improvement Grant Program for Commercial & Mixed-Use Properties. Donor Name: Alpena Downtown Development Authority State: Michigan City: Alpena Type of Grant: Grant Deadline: 05/24/2024 Size of the Grant: Not Available Grant Duration: Grant Duration Not Mentioned Details: In October 2023, the Alpena DDA was awarded $400,000 grant through the Michigan Economic Development Corporation (MEDC) through its Façade Restoration Initiative (FRI) Program to supplement our local program. Projects may now apply for grants of 50% of their façade project total. All projects must be complete by April 30, 2025. Funding Information The Design Committee may award grants under the program in any amount requested from a minimum award of $500.00 to up to 50% of eligible renovation costs. All requests must be approved by the DDA Board. Building Eligibility Requirements Location and Nature of Building Use.  Properties located within the legal boundary of Alpena’s DDA district engaging in retail, restaurant, commercial, entertainment, office services, or properties that are mixed- use shall be deemed eligible for grant funding. Any question concerning the eligibility of a specific property may be submitted to the Executive Director of the DDA. A determination of location and building use eligibility will be provided to the interested party within two business days following receipt of the inquiry. Payment of Taxes and Other Public Accounts. All previously billed and currently payable property taxes and annual installments of assessments must be paid in full for the subject property before an application for a façade improvement grant will be considered. Additionally, all City of Alpena accounts in the name of the applicant and/or attaching to the subject property must be current. All taxes, assessments, and other city accounts must be kept current during the application, review, construction, and post-construction processes. Nature of Façade. Grant funding may be requested for any façade (front, side, or rear) that fronts on a public right of way (street, alley, or public parking lot). Applicants may apply for up to 50% of eligible renovation costs per façade. All requests for funding must be approved by the DDA Board of Directors. Greater consideration for funding will be given to work proposed on a façade fronting a city street. Structural Integrity of Building. Buildings for which improvements are proposed must have basic structural integrity and an intact roof as confirmed by the City of Alpena Building Department, thereby protecting the DDA’s potential investment in the façade. Insurance Coverage. The applicant or the owner of the subject property must carry suitable property insurance coverage on the subject property and must provide a certificate of coverage to the DDA with the application. The applicant or owner is strongly encouraged to also carry a builder’s risk policy of insurance covering potential damage to the building’s structure by the contractor. For more information, visit Alpena DDA.

This program provides funding to state entities, higher education institutions, and private businesses in Texas to support new and expanded semiconductor research, design, and manufacturing projects.

Governor Greg Abbott and the Texas Division of Emergency Management (TDEM) have announced the opening of applications for the Department of Energy's (DOE) grant program aimed at enhancing the resilience of electric grids against disruptive events. The program is designed to allocate competitive grants to improve infrastructure and reduce the likelihood and impact of such events on the electrical grid. The grant supports weatherization, fire-resistant technologies, monitoring and control systems, vegetation management, adaptive protections, and advanced modeling technologies. This grant opportunity is now active with a closing deadline of June 28, 2024.

The Water Resources Preservation Grant Program, funded by the Upper Guadalupe River Authority (UGRA), provides cost-share funding to support the design and construction of stormwater management practices. These practices, referred to as Best Management Practices (BMPs), include Low Impact Development (LID), nature-based solutions, and Green Stormwater Infrastructure (GSI). The goal is to reduce, infiltrate, filter, and delay stormwater runoff, thus protecting the health of waterways in Kerr County. Eligible projects can apply for rebates that cover a portion of the costs associated with these practices, with the aim of reducing pollutants like Total Suspended Solids (TSS) and Bacteria by significant percentages. The program supports new constructions or retrofits, emphasizes distributed and centralized treatment methods, and requires adherence to specific design guidelines.

This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and pre-cancer in underserved populations who do not have adequate access to cancer early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers. Award: Maximum of $1M for new projects and $2.5M for expansion projects Duration: Maximum 5 years

This funding opportunity supports early-career scientists transitioning to small business roles by providing financial resources for clinical trials, mentorship, and entrepreneurial training to foster their development and commercialization of innovative technologies.